Sichenzia Ross Ference Kesner LLP Represents Cannabinoid Based Therapeutics Company in $12.3 Million Private Placement Led by Tuatara Capital Fund I, Ltd.
Press Release – New York, NY – March 2, 2017 – Securities and corporate law firm Sichenzia Ross Ference Kesner LLP is pleased to announce that the firm has represented a cannabinoid based life sciences corporation whose technology is designed to synthetically produce medically beneficial cannabinoids without utilizing the actual cannabis plant for the customized treatment of disease.
Last year, Tuatara and its affiliates invested $7.0 million in a Series A Financing for the company. The Sichenzia Ross Ference Kesner LLP team was led by partners Darrin M. Ocasio and Arthur Marcus and associate S. Ashley Jaber. Sichenzia Ross Ference Kesner LLP is a leader in the representation of cannabis related companies.
Visit SRFK's LinkedIn page
Latest posts by Sichenzia Ross Ference Kesner LLP (see all)
- Sichenzia Ross Ference Kesner LLP Advises Laidlaw & Co. (UK) Ltd. on U.S. Public Offering and NASDAQ Listing of Israeli Cannabinoid Research Company Therapix Biosciences, Ltd. (TRPX) - March 24, 2017
- Sichenzia Ross Ference Kesner LLP Represents XTL Biopharmaceuticals Ltd., in a $2.8 Million Private Placement of ADSs. - March 23, 2017
- Sichenzia Ross Ference Kesner LLP Represents Rodman & Renshaw a unit of H.C Wainwright in $3.85 Million Public Offering of Innovus Pharmaceuticals, Inc. - March 22, 2017